Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 25, 2026, 2:04 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 169–192 of 282 matching trials from the live ClinicalTrials.gov search.
Conditions
Fertility Preservation
Interventions
Oophorectomy
Procedure
Lead sponsor
Baylor College of Medicine
Other
Eligibility
0 Years to 42 Years · Female only
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
1
States / cities
Houston, Texas
Completed Phase 2Phase 3 Interventional Results available

Scleroderma: Cyclophosphamide or Transplantation

NCT00114530
Conditions
Scleroderma, Systemic, Sclerosis, Autoimmune Disease
Interventions
mHSCT, cyclophosphamide
Biological · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 69 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2016
U.S. locations
15
States / cities
Duarte, California • Los Angeles, California • Lexington, Kentucky + 10 more
Conditions
Infertility
Interventions
Viacell's product Media Kits
Device
Lead sponsor
ViaCell
Industry
Eligibility
21 Years to 35 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
4
States / cities
San Ramon, California • South Miami, Florida • Iowa City, Iowa + 1 more
Terminated No phase listed Observational Accepts healthy volunteers

Oocyte Cryopreservation Study (Egg Banking)

NCT02396095
Conditions
Cancer
Interventions
Not listed
Lead sponsor
University of Pennsylvania
Other
Eligibility
15 Years to 45 Years · Female only
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2013
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Locally Advanced Pancreatic Adenocarcinoma, Metastatic Pancreatic Adenocarcinoma
Interventions
EGFR BATs after standard of care chemo
Drug
Lead sponsor
University of Virginia
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
1
States / cities
Charlottesville, Virginia
Conditions
Osteochondral Defect
Interventions
osteochondral transplant on the femoral condyle
Procedure
Lead sponsor
AlloSource
Industry
Eligibility
12 Years to 60 Years
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2031
U.S. locations
6
States / cities
Phoenix, Arizona • Los Angeles, California • Redwood City, California + 3 more
Conditions
Oropharyngeal Dysphagia
Interventions
Autologous Muscle Derived Cells for Gastro-Intestinal Repair (AMDC-GIR), Placebo
Biological · Other
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years and older
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
2
States / cities
Sacramento, California • San Francisco, California
Conditions
Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q), Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(15;17)(q22;q12), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22), Adult Acute Myeloid Leukemia With t(8;21)(q22;q22), Childhood Acute Lymphoblastic Leukemia in Remission, Childhood Acute Myeloid Leukemia in Remission, Childhood Chronic Myelogenous Leukemia, Childhood Myelodysplastic Syndromes, Chronic Phase Chronic Myelogenous Leukemia, de Novo Myelodysplastic Syndromes, Previously Treated Myelodysplastic Syndromes, Refractory Anemia, Refractory Anemia With Excess Blasts, Refractory Anemia With Excess Blasts in Transformation, Relapsing Chronic Myelogenous Leukemia, Secondary Myelodysplastic Syndromes
Interventions
umbilical cord blood transplantation, fludarabine phosphate, cyclophosphamide, ex vivo-expanded cord blood progenitor cell infusion, total-body irradiation, cyclosporine, mycophenolate mofetil, laboratory biomarker analysis
Procedure · Drug · Biological + 2 more
Lead sponsor
Nohla Therapeutics, Inc.
Industry
Eligibility
6 Months to 45 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Seattle, Washington
Conditions
Breast Cancer, Infertility
Interventions
Letrozole
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
19 Years to 45 Years · Female only
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2022
U.S. locations
1
States / cities
New York, New York
Conditions
Acute Myeloid Leukemia
Interventions
WU-NK-101
Biological
Lead sponsor
Allotera Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
6
States / cities
Duarte, California • Palo Alto, California • Louisville, Kentucky + 3 more
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Evaluation of Whole Blood With CPD Anticoagulant and AS-7/SOLX Additive Solution

NCT02145507
Conditions
Blood Donors
Interventions
SOLX (Investigational), AS-3 (Control)
Drug
Lead sponsor
Haemonetics Corporation
Industry
Eligibility
18 Years and older
Enrollment
170 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
2
States / cities
Cincinnati, Ohio • Norfolk, Virginia
Conditions
Lung Carcinoma, Lung Neoplasm, Malignant Lung Neoplasm
Interventions
cytology specimen collection procedure
Other
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2022
U.S. locations
19
States / cities
Lewes, Delaware • Newark, Delaware • Elkton, Maryland + 14 more
Terminated Not applicable Interventional

FLO for Discogenic Pain

NCT03644251
Conditions
Discogenic Back Pain
Interventions
amniotic and umbilical cord matrix
Other
Lead sponsor
BioTissue Holdings, Inc
Industry
Eligibility
18 Years to 70 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Tampa, Florida
Completed Phase 1Phase 2 Interventional Results available

Stem Cell Gene Therapy for Cystinosis

NCT03897361
Conditions
Lysosomal Storage Diseases, Cystinosis
Interventions
CTNS-RD-04 (including CTNS-RD-04-LB manufactured with LentiBOOST)
Genetic
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
La Jolla, California
Conditions
Idiopathic Pulmonary Fibrosis, Emphysema or COPD
Interventions
CD3/CD19 negative hematopoietic stem cells, Rituximab, Alemtuzumab, Fludarabine, Thiotepa, G-CSF, Hydroxyurea
Biological · Drug
Lead sponsor
Paul Szabolcs
Other
Eligibility
18 Years to 60 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2028
U.S. locations
2
States / cities
Pittsburgh, Pennsylvania
Terminated Not applicable Interventional Accepts healthy volunteers

Oocyte Cryopreservation

NCT01232972
Conditions
Fertility
Interventions
vitrification of oocytes
Procedure
Lead sponsor
Northwell Health
Other
Eligibility
18 Years to 42 Years · Female only
Enrollment
23 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2013
U.S. locations
1
States / cities
Manhasset, New York
Conditions
Knee Osteoarthritis
Interventions
Amniotic Suspension Allograft, Placebo
Biological · Drug
Lead sponsor
Organogenesis
Industry
Eligibility
18 Years and older
Enrollment
516 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
38
States / cities
Birmingham, Alabama • Mobile, Alabama • Glendale, Arizona + 30 more
Completed Phase 1 Interventional Results available

FT516 and IL2 With Enoblituzumab for Ovarian Cancer

NCT04630769
Conditions
Ovarian Cancer, Fallopian Tube Adenocarcinoma, Primary Peritoneal Cavity Cancer
Interventions
IP FT516, Enoblituzumab, IL-2
Drug
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Minneapolis, Minnesota
Completed Phase 1Phase 2 Interventional Results available

Bilateral Orthotopic Lung Transplant - Bone Marrow Transplant

NCT03330795
Conditions
Primary Immunodeficiency, PID
Interventions
CD3/CD19 neg allogeneic BMT
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
10 Years to 45 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Conditions
Idiopathic Inflammatory Myositis (IIM), DERMATOMYOSITIS OR POLYMYOSITIS
Interventions
ULSC (1.5 x 10^8 cells/dose), Placebo (no cells)
Biological
Lead sponsor
Restem, LLC.
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
2
States / cities
Gainesville, Florida • Miami, Florida
Conditions
Hematologic Malignancies, Inherited Disorders of Metabolism, Inherited Abnormalities of Platelets, Histiocytic Disorders, Acute Myelogenous Leukemia (AML or ANLL), Acute Lymphoblastic Leukemia (ALL), Other Acute Leukemia, Chronic Myelogenous Leukemia (CML), Myelodysplastic (MDS) / Myeloproliferative (MPN) Diseases, Other Leukemia, Hodgkin Lymphoma, Non-hodgkin Lymphoma, Multiple Myeloma/ Plasma Cell Disorder (PCD), Inherited Abnormalities of Erythrocyte Differentiation or Function, Disorders of the Immune System, Autoimmune Diseases, Severe Aplastic Anemia
Interventions
A multicenter access and distribution protocol for unlicensed cryopreserved cord blood units (CBUs)
Drug
Lead sponsor
Center for International Blood and Marrow Transplant Research
Network
Eligibility
Not listed
Enrollment
99,999 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2041
U.S. locations
142
States / cities
Birmingham, Alabama • Gilbert, Arizona • Phoenix, Arizona + 90 more
Not listed No phase listed Observational Accepts healthy volunteers

Oocyte Cryopreservation: Evaluation of an Oocyte Freezing and Thawing Technique

NCT00713869
Conditions
Infertility
Interventions
Not listed
Lead sponsor
West Coast Fertility Centers
Other
Eligibility
21 Years to 45 Years · Female only
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2011
U.S. locations
1
States / cities
Fountain Valley, California
Conditions
Hematological Malignancy
Interventions
Fludarabine Phosphate, Cyclophosphamide, CAR.5/IL15-transduced CB-NK cells
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
1
States / cities
Houston, Texas
Conditions
Breast Cancer
Interventions
Ovarian stimulation in vitro fertilization cryopreservation
Procedure
Lead sponsor
New York Medical College
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2018
U.S. locations
1
States / cities
Valhalla, New York